免疫检查点抑制剂介导的肝毒性的研究进展  

Research progress of immune checkpoint inhibitor mediated hepatotoxicity

作　　者：周皓洁 余一祎[1] Zhou Haojie;Yu Yiyi(Department of Oncology,Zhongshan Hospital,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学附属中山医院肿瘤科,上海200032

出　　处：《肿瘤综合治疗电子杂志》2023年第3期9-14,共6页Journal of Multidisciplinary Cancer Management(Electronic Version)

摘　　要：10余年来,免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)的应用在肿瘤治疗中取得了瞩目成就。然而,随着ICIs使用的增多和适应证的扩大,免疫相关不良事件(immune-related adverse events,irAEs)也随之增加。在这些不良反应中,免疫治疗介导的肝毒性(immunotherapy mediated hepatotoxicity,IMH)的发病率为1%~15%。本文结合近期的研究报道,对IMH的发生机制、诊断、治疗及预后等作一综述,为临床工作中IMH的诊治提供相关信息。In the last decade,remarkable achievements have been made in anti-tumor treatment of immune checkpoint inhibitors(ICIs).However,immune-related adverse events(irAEs)increased with the increasing use and expansive indications of ICIs.Among irAEs,the incidence of immunotherapy meditated hepatotoxicity(IMH)ranged from 1%-15%.Based on recent studies,we made a review of the pathogenesis,diagnosis,treatment and prognosis of IMH to guide the diagnosis and treatment of IMH in clinical work.

关 键 词：免疫检查点抑制剂 肝毒性 肝炎 胆管炎 

分 类 号：R730.5[医药卫生—肿瘤]